Rentschler Biopharma and Coriolis Pharma have announced a strategic partnership to provide fully integrated biopharmaceutical solutions, spanning early formulation to commercial manufacturing. The collaboration unites Rentschler’s expertise in bioprocess development and reliable large-scale manufacturing with Coriolis’s strengths in formulation research, analytical services, and drug product development. This combination offers clients a streamlined path from discovery to market while reducing technical transfer risks and accelerating project timelines.

Clients will benefit from a single point of contact and aligned project teams covering research and development, clinical testing, and manufacturing stages. Coriolis brings advanced in silico and wet lab capabilities, deep scientific insight, and robust analytical proficiency, while Rentschler delivers a proven track record in process development and the manufacture of multiple biotherapeutics. Together, the organisations address increasing complexity in biologic modalities and rising regulatory requirements through a connected, science-driven approach.

Operations in Germany and the United States provide global reach with local access, ensuring seamless support across key biopharmaceutical markets. The integrated service will be available from December 2025, enabling clients to advance efficiently from early development through clinical trials and commercial production without disruption.

This partnership exemplifies the sector’s shift towards end-to-end, integrated service models that prioritise speed, reliability, and consistency. By combining complementary technical expertise, aligned workflows, and a client-focused interface, Rentschler and Coriolis provide a cohesive approach that reduces risk and drives innovation. The collaboration demonstrates how strategic alignment and scientific depth can meet complex project demands while accelerating outcomes across the biopharmaceutical value chain.

Read the full article to explore how this partnership is redefining the delivery and development of biopharmaceutical products.